Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Does rapid dose titration affect the hepatic safety profile of Bosentan?

0
Posted

Does rapid dose titration affect the hepatic safety profile of Bosentan?

0

Author(s): Suntharalingam J, Hodgkins D, Cafferty FH, Hughes RJ, Pepke-Zaba J Affiliation(s): Clinical Research Fellow, Pulmonary Vascular Diseases Unit, Papworth Hospital NHS Trust, Papworth Everard, Cambridgeshire, CB3 8RE, United Kingdom. jay.suntharalingam@papworth.nhs.uk Publication date & source: 2006-06, Vascul Pharmacol., 44(6):508-12. Epub 2006 May 19. Publication type: Clinical Trial RATIONALE: Bosentan, a dual endothelin receptor antagonist, has proven efficacy in pulmonary hypertension. Due to an association with hepatic dysfunction, it is typically initiated at a sub-therapeutic dose for 4 weeks before titration to a therapeutic dose. At our institution some patients have undergone rapid titration, to potentially benefit from therapy earlier. This study assesses the impact of this practice on hepatic safety. METHOD: All patients initiated on bosentan therapy before April 2005 were included. Rapidly titrated patients achieved a therapeutic dose by 3 days, whereas standard t

Related Questions

Thanksgiving questions

*Sadly, we had to bring back ads too. Hopefully more targeted.